Abstract Background Coronavirus disease 2019 (COVID-19), caused by the novel
coronavirus SARS-CoV-2, has led to significant global mortality and morbidity. Until now, no …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has become a global health
crisis. Considering the recent food and drug administration (FDA) approval of remdesivir as …

Background Efficacy of remdesivir for COVID-19 remains unclear. We updated our
published systematic review to better inform on the use of remdesivir for COVID-19. Methods …

Background The first cases of the coronavirus disease 2019 (COVID-19) were reported in
Wuhan, China. No antiviral treatment options are currently available with proven clinical …

Background The nucleotide analogue prodrug remdesivir was among the first antiviral
therapies to be tested in randomized controlled trials (RCTs) for COVID-19. We performed a …

Background In view of many unanswered clinical questions regarding treatment of COVID-
19 with remdesivir, we systematically identified, critically appraised and summarized the …

Remdesivir is an antiviral agent that has shown broad‐spectrum activity, including against
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clinical trials investigating …

Objective This living systematic review aims to provide a timely, rigorous and continuously
updated summary of the evidence available on the role of remdesivir in the treatment of …

BACKGROUND Remdesivir, an inhibitor of viral RNA-dependent RNA polymerases, has
been identified as a candidate for COVID-19 treatment. However, the therapeutic effect of …

Background Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We
systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19 …